Sign In
Buy MRK
$115.49
+0.320 (+0.278%)
At Close: Jun 17, 2026
Key Factors Driving Merck's (MRK) Outperformance This Year
02:59pm, Wednesday, 14'th Sep 2022
Strong sales of key products like Keytruda and Gardasil, a significant contribution from Lagevrio and positive pipeline/regulatory developments have been keeping Merck's (MRK) stock afloat in 2022.
Analyst: Merck Stock is a "Low-Risk Value Option"
09:22am, Wednesday, 14'th Sep 2022
According to a Berenberg bull note, Merck & Co., Inc. (NYSE:MRK) is a solid "low-risk value option" in the pharmaceutical sector.
The 7 Best Retirement Stocks to Buy Now
07:37am, Tuesday, 13'th Sep 2022
Today, we introduce several of the best retirement stocks to buy in September. For many Americans, growing retirement savings is a primary motivation for buying shares on Wall Street.
Merck & Co., Inc. (MRK) Presents at Morgan Stanley 20th Annual Global Healthcare Conference (Transcript)
06:30pm, Monday, 12'th Sep 2022
Merck & Co., Inc. (NYSE:MRK ) Morgan Stanley 20th Annual Global Healthcare Conference September 12, 2022 2:15 PM ET Company Participants Rob Davis - Chief Executive Officer Dean Li - Head of R&D Confe
Merck Gambled With Keytruda In 2011 — How That Jump Is Still Paying Off Today
04:15am, Sunday, 11'th Sep 2022
A gamble could pay off for Merck stock after blockbuster Keytruda nearly doubled the five-year survival rate for some lung cancer patients. The post Merck Gambled With Keytruda In 2011 — How That Ju
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
10:32am, Thursday, 08'th Sep 2022
Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Pfizer's Peer Appears To Be A Better Pharmaceuticals Pick
10:00am, Thursday, 08'th Sep 2022
There is more to the comparison, and in the sections below, we discuss why we believe MRK stock will offer better returns than PFE stock in the next three years.
Merck Benefits From Diagnosis Rate Pickup, Limited Risk To Medicare Bills
08:00am, Thursday, 08'th Sep 2022
Merck delivers a great quarter led by their blockbuster Keytruda as well as other oncology and vaccine recovery. As a seller of one of the U.S.' largest blockbusters, there are some regulatory risks o
A Pair of Undervalued Stocks Crushing the S&P 500 Index
10:56am, Wednesday, 07'th Sep 2022
The S&P 500 Index has lost nearly 18% year to date as the markets continue to trend lower. Interest rate hikes, high inflation, supply chain constraints, Covid-19 restrictions, the Russian invasion of
Merck: 4 Reasons To Choose A Green Pill
10:00am, Wednesday, 07'th Sep 2022
Combining effectiveness in the treatment of many types of cancer, extensive research activities, and rapid sales growth, Keytruda will remain a key driver of Merck. Merck has a large pipeline and non-
Merck's Deal With Seagen May Have Fallen Through. Now What?
06:12am, Wednesday, 07'th Sep 2022
A steep valuation may force Merck to look elsewhere for portfolio growth.
Merck to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
06:45am, Tuesday, 06'th Sep 2022
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Robert M. Davis, chief executive officer and president, and Dr.
Merck (MRK) Stock Moves -1.06%: What You Should Know
09:45pm, Friday, 02'nd Sep 2022 Zacks Investment Research
In the latest trading session, Merck (MRK) closed at $86.23, marking a -1.06% move from the previous day.
Investors favor stocks with stable, visible cash flows, says Bryn Mawr Trust's Jeff Mills
02:40pm, Friday, 02'nd Sep 2022
Jeff Mills, CIO at Bryn Mawr Trust, joins 'The Exchange' to discuss his three "buys" and a "bail" across healthcare, energy, and tech sectors, singling out favorites: Cheniere, Merck, and Danaher.
3 Stocks to Buy in September as the Market Falls and Rates Rise
10:00am, Friday, 02'nd Sep 2022 Zacks Investment Research
Diving into three dividend-paying stocks that could be poised to help investors profit in September and beyond.
